A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

U Baumhackl; L Kappos; E W Radue; P Freitag; A Guseo; M Daumer; J Mertin

doi:10.1191/1352458505ms1132oa

A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

Mult Scler. 2005 Apr;11(2):166-8. doi: 10.1191/1352458505ms1132oa.

Authors

U Baumhackl¹, L Kappos, E W Radue, P Freitag, A Guseo, M Daumer, J Mertin

Affiliation

¹ Department of Neurology, Central Clinic, St Poelten, Austria. [email protected]

PMID: 15794389
DOI: 10.1191/1352458505ms1132oa

Abstract

Oral administration of hydrolytic enzymes (HE), such as bromelain, trypsin and rutosid, may have beneficial effects on the clinical course of neurological symptoms related to multiple sclerosis (MS). This is supported by a complete protection by HE from experimental allergic encephalomyelitis, an animal model related to MS. Three hundred and one patients with relapsing MS were enrolled in a double-blind, placebo-controlled trial. No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Adult
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
Bromelains / administration & dosage*
Double-Blind Method
Female
Humans
Magnetic Resonance Imaging
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / pathology
Placebos
Recurrence
Rutin / administration & dosage
Rutin / analogs & derivatives*
Treatment Outcome
Trypsin / administration & dosage*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Placebos
rutin sulfate
Rutin
Bromelains
Trypsin